Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Tobira Therapeutics, Inc.
Information provided by (Responsible Party):
Tobira Therapeutics, Inc. Identifier:
First received: January 8, 2016
Last updated: April 18, 2016
Last verified: April 2016
This is a single-arm, open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult subjects with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.

Condition Intervention Phase
Primary Sclerosing Cholangitis
Drug: Cenicriviroc 150 mg
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis

Resource links provided by NLM:

Further study details as provided by Tobira Therapeutics, Inc.:

Primary Outcome Measures:
  • Percent change from baseline through Week 24 in serum alkaline phosphatase [ Time Frame: 24 weeks ]

Other Outcome Measures:
  • Proportion of subjects with treatment-emergent adverse event [ Time Frame: 24 weeks ]

Estimated Enrollment: 25
Study Start Date: February 2016
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open-label
One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks
Drug: Cenicriviroc 150 mg
One tablet of CVC 150 mg once daily taken with food in the morning
Other Name: CVC 150 mg


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with chronic cholestatic liver disease for at least 6 months
  • Clinical diagnosis of PSC as evident by chronic cholestasis of more than six months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis, or a liver biopsy taken at any time consistent with PSC in the absence of a documented alternative etiology for sclerosing cholangitis. If diagnosis of PSC was made by histology alone, it must require the presence of fibro-obliterative lesions (ie, onion skin lesions)
  • Documented evidence of Inflammatory Bowel Disease (IBD) either by prior endoscopy or in previous medical records, for >= 6 months. In addition, subjects will be required to enter the study with a Partial Mayo Risk score of 0-3, inclusively
  • In subjects receiving treatment with ursodeoxycholic acid (UDCA), therapy must be stable for at least 3 months, and at a dose not greater than 20 mg/kg/day
  • Serum ALP greater than 1.5 × upper limit of normal (ULN)
  • Ability to understand and sign a written informed consent form (ICF)
  • Subjects receiving allowed concomitant medications need to be on stable therapy for 28 days prior to the Baseline Visit

Exclusion Criteria:

  • Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic slerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis) on prior clinical investigations
  • Small duct PSC
  • Presence of percutaneous drain or bile duct stent
  • History of cholangiocarcinoma or high clinical suspicion over dominant stricture within 1 year by MRCP/ERCP or clinical judgment
  • Ascending cholangitis within 60 days prior to Screening
  • Alcohol consumption greater than 21 units/week for males or 14 units/week for females (one unit of alcohol is ½ pint of beer [285 mL], 1 glass of spirits [25 mL] or 1 glass of wine [125 mL])
  • Prior or planned liver transplantation
  • Presence of alternative causes of chronic liver disease, including alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis
  • History of cirrhosis and/or hepatic impairment (Child-Pugh classes A, B and C) and/or hepatic decompensation including ascites, encephalopathy or variceal bleeding. Subjects who show evidence of significant worsening of hepatic function will be excluded
  • Subjects with fibrosis evidence of cirrhosis, as determined by local transient elastography (TE, e.g., Fibroscan) values of >= 13.0 kPa, taken within the last 6 months. If TE has not been conducted within the 6 months prior to screening then one will be conducted during the screening period and can be used as the Baseline value.
  • Moderate to Severe active IBD or flare in colitis activity within the last 90 days requiring intensification of therapy beyond Baseline treatment. Subjects with stable mild to moderate IBD, who are on treatment, are allowed provided they are stable for 3 months with 5-amino salicylic acid drugs or Azathioprine (allowed dose of azathioprine is 50-200 mg/day)
  • Use of oral prednisolone > 10 mg/day, biologics and/or hospitalization for colitis within 90 days are disallowed
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT); above the allowed cut-offs, as determined by the mean Screening and pre-Baseline values (subjects who show evidence of significant worsening of liver transaminases on repeat measure will be excluded):

    • AST > 200 IU/L males and females
    • ALT: males > 250 IU/L and females > 200 IU/L
  • Total Bilirubin and Direct Bilirubin; above the allowed cut-offs, as determined by the mean Screening and pre-Baseline values (subjects who show evidence of significant worsening of bilirubin will be excluded):

    • Total Bilirubin ≥ 1.5 mg/dL
    • Direct Bilirubin ≥ 0.5 mg/dL
  • International normalized ratio > 1.3 in the absence of anticoagulants
  • Immunoglobulin G4 (IgG4) > 4 × ULN at Screening or evidence of IgG4-related sclerosing cholangitiss
  • Females who are pregnant or breastfeeding
  • Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02653625

Contact: William Chang, JD

United States, California
Sacramento, California, United States
Not yet recruiting
San Francisco, California, United States
United States, Florida
Miami, Florida, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Minnesota
Not yet recruiting
Rochester, Minnesota, United States
United States, New York
Not yet recruiting
New York City, New York, United States
Canada, Alberta
Calgary, Alberta, Canada
Not yet recruiting
Edmonton, Alberta, Canada
Canada, Manitoba
Winnepeg, Manitoba, Canada
Canada, Ontario
Not yet recruiting
Toronto, Ontario, Canada
Sponsors and Collaborators
Tobira Therapeutics, Inc.
Study Director: Pamela Vig, PhD Tobira Therapeutics, Inc.
  More Information

Responsible Party: Tobira Therapeutics, Inc. Identifier: NCT02653625     History of Changes
Other Study ID Numbers: 652-205
Study First Received: January 8, 2016
Last Updated: April 18, 2016

Keywords provided by Tobira Therapeutics, Inc.:
Primary Sclerosing Cholangitis

Additional relevant MeSH terms:
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
CCR5 Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents processed this record on April 24, 2017